|
 |
|
| Composition w/v |
|
| Omega 3 fatty acids 500 mg containing |
|
| Eicosapentaenoic Acid (EPA) |
180 mg |
| Docosahexaenoic Acid (DHA) |
120 mg |
|
|
|
| Dosage form |
| Capsules |
|
| Category |
| Antioxidant |
|
| Mechanism of action |
Increased TNF-a in the lacrimal gland increases lacrimal gland apoptosis ( programmed cell death). Increased apoptosis contributes to decreased in tear production & increase in tearfilm osmolarity that drives dry eye ocular surface disorder.
EPA & DHA elongated with enzymes produces anti inflammatory prostaglandin E3 (PGE 3) & leukotrienes B5 (LTB 5)
EPA blocks the gene expression of pro inflammatory cytokines tumor necrosis factor alpha (TNF a), interleukin-1a (IL-1a), interleukin-1b (IL-1), proteoglycan degrading enzymes & cyclo oxygenase and thus reduces the imflammation.
Meibomian glands use essential fatty acids to synthesize oil. Omega 3 fatty acids clears & thins the meibomian gland secretions & stimulates tear secretions. |
|
| Indications |
| Lacriguard is indicated for chronic dry eyes. |
|
| Dosage |
| The recommended dose of Lacriguard is one capsule a day. |
|
| Storage |
| Store in a cool dry place. Protect from light. |
|
| Presentation |
| LACRIGUARD is available in a blister pack of 10 capsules. |
|
